Introduction: Despite the proven benefit of adjuvant androgen deprivation therapy (ADT) for patients receiving primary radiation, few studies evaluate adjuvant ADT after prostatectomy. We surveyed Canadian prostate cancer patients about adjuvant ADT with the goal of informing an adjuvant ADT clinical trial. Methods: An electronic survey was devised and distributed using a modified Dillman approach. The survey was sent to members of Prostate Cancer Canada, a patient advocacy group. In addition to demographic information, we asked patients about their experience with prostate cancer, if they received post-operative therapy, and about their opinions to inform the design of an adjuvant ADT clinical trial. The survey was sent on May 2021, and all responses were received by July 2021. Results: Forty patients completed the survey. The average participant age was 71±7.3 years old. The average age at prostate cancer diagnosis was 64 ±6.7 years. Thirty-eight (95%) patients were previously treated with radical prostatectomy and 24 (60%) subsequently developed biochemical recurrence. If it had been available, 30 (75%) participants indicated that they would have been interested in an adjuvant ADT trial to prevent biochemical recurrence. Most (15; 37.5%) stated that 12 months would be the longest duration of ADT that they would consider. The remainder of participants would have considered up to 6 months (9;22.5%), up to 18 months (3;7.5%), up to 24 months (5;12.5%), or greater than 24 months (8;20%) of adjuvant ADT. A daily oral tablet (31; 52.5%) or injection every 6 months (9; 22.5%) were favoured in a clinical trial over an injection at shorter time intervals. The most important outcomes for a trial of adjuvant ADT were prevention of cancer related death (38; 95%) and cancer recurrence (37; 92%). If 1 year of adjuvant ADT reduced PSA recurrence by 50%, many (29; 47.5%) stated they would have chosen this intervention. Conclusions: Few trials have assessed adjuvant ADT after radical prostatectomy and many patients claim they would have been interested in participating in a trial if it had been available. Based on these results, a randomized trial is warranted and patient preferences should be incorporated in trial design. SOURCE OF Funding: None
